Fascin expression is inversely correlated with breast cancer metastasis suppressor 1 and predicts a worse survival outcome in node-negative breast cancer patients

被引:17
作者
Lee, Hye Jin [1 ]
An, Hee Jung [1 ]
Kim, Tae Hoen [1 ]
Kim, Gwangil [1 ]
Kang, Haeyoun [1 ]
Heo, Jin Hyung [1 ]
Kwon, Ah-Young [1 ]
Kim, Sewha [1 ]
机构
[1] CHA Univ, CHA Bundang Med Ctr, Dept Pathol, 59 Yatap Ro, Seongnam Si 13496, Gyeonggi Do, South Korea
来源
JOURNAL OF CANCER | 2017年 / 8卷 / 16期
关键词
breast cancer; fascin; breast cancer metastasis suppressor 1; immunohistochemistry; AGGRESSIVE CLINICAL-COURSE; CARCINOMA METASTASIS; ACTIN CYTOSKELETON; OVARIAN-CARCINOMA; BRMS1; PROTEIN; CELLS; MIGRATION; MOTILITY; MARKER;
D O I
10.7150/jca.22046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Fascin is an actin-bundling protein that promotes cancer cell migration and invasion. By contrast, breast cancer metastasis suppressor 1 (BRMS1) inhibits cancer metastasis by targeting multiple steps of the metastatic cascade. We evaluated whether expression patterns of fascin and BRMS1 correlate with clinicopathological features and patient outcome. Methods: Immunohistochemistry for fascin and BRMS1 was performed using a tissue microarray constructed from 183 human breast cancer tissues. Fascin expression determined by the proportion of stained tumor cells (0: 0-5%, 1: 6-25%, 2: 26-50%, 3: 51-75%, or 4: >75%) and staining intensity (0: negative, 1: weak, 2: moderate, or 3: strong) were multiplied and defined as negative (0-3) or positive (4-12). BRMS1 expression was scored separately based on nuclear and cytoplasmic staining intensity (0: negative, 1: weak, 2: moderate, 3: strong). We obtained the BRMS1 H score by summing the nuclear and cytoplasmic scores and defined it as negative (0-2) or positive (3-6). Results: Expression of BRMS1 showed a significant inverse correlation with that of fascin. Fascin(+) tumors were significantly associated with no lymph node metastasis, higher histological and higher nuclear grade, ER/PR/HER2 negativity, and triple-negative subtype (all ps < 0.05). These clinicopathological differences showed the same trend in a comparison of fascin(-)/BRMS1(+) and fascin(+)/BRMS1(-) tumors. Negative or weak BRMS1 cytoplasmic expression was significantly associated with shorter disease-free survival (DFS; p = 0.043). Fascin positivity was significantly associated with shorter DFS (p = 0.005) and overall survival (p = 0.020) when analyses were confined to node-negative patients. Conclusions: This study confirms an inverse correlation between expression of fascin and expression of BRMS1 using a quite large cohort of human breast cancer tissues. Fascin alone or combined with BRMS1 was a worse prognostic marker, particularly in node-negative breast cancer patients.
引用
收藏
页码:3122 / 3129
页数:8
相关论文
共 50 条
  • [31] Risk Factors Associated With Sentinel Lymph Node Metastasis in Clinically Node-Negative Breast Cancer
    Abdulla, Hussain Adnan
    Salman, Ahmed Zuhair
    Alaraibi, Sarah Jawad
    Nazzal, Khaled
    Ahmed, Sara Abdulameer
    Almahari, Sayed Ali
    Dhaif, Ali
    EUROPEAN JOURNAL OF BREAST HEALTH, 2023, 19 (03) : 229 - 234
  • [32] Tumor angiogenesis in node-negative breast cancer: Relationship with relapse free survival
    Karaiossifidi, H
    Kouri, E
    Arvaniti, H
    Sfikas, S
    Vasilaros, S
    ANTICANCER RESEARCH, 1996, 16 (6C) : 4001 - 4002
  • [33] Breast cancer metastasis suppressor gene, breast cancer metastasis suppressor 1, may be associated with clinicopathological features of breast cancer
    Lin, Lizhong
    Cai, Miaoguo
    Dai, Yuechu
    Zheng, Zhibao
    Jiang, Fangfang
    Shi, Lili
    Pan, Yin
    Song, Han-Bing
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S368 - S374
  • [34] Prognostic impact of tumor biological factors on survival in node-negative breast cancer
    Harbeck, N
    Dettmar, P
    Thomssen, C
    Henselmann, B
    Kuhn, W
    Ulm, K
    Jänicke, F
    Höfler, H
    Graeff, H
    Schmitt, M
    ANTICANCER RESEARCH, 1998, 18 (3C) : 2187 - 2197
  • [35] A prospective, multicenter validation study of a prognostic index composed of S-phase fraction, progesterone receptor status, and tumour size predicts survival in node-negative breast cancer patients: NNBC, the node-negative breast cancer trial
    Klintman, M.
    Nilsson, F.
    Bendahl, P. -O.
    Ferno, M.
    Liljegren, G.
    Emdin, S.
    Malmstrom, P.
    Grp, Swedish Breast Cancer
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2284 - 2291
  • [36] Axillary recurrence in sentinel lymph node-negative breast cancer patients
    Poletti, P.
    Fenaroli, P.
    Milesi, A.
    Paludetti, A.
    Mangiarotti, S.
    Virotta, G.
    Candiago, E.
    Bettini, A.
    Caremoli, E. R.
    Labianca, R.
    Tondini, C.
    ANNALS OF ONCOLOGY, 2008, 19 (11) : 1842 - 1846
  • [37] Cell proliferation in breast cancer is a major determinant of clinical outcome in node-positive but not in node-negative patients
    Trere, Davide
    Ceccarelli, Claudio
    Migaldi, Mario
    Santini, Donatella
    Taffurelli, Mario
    Tosti, Elena
    Chieco, Pasquale
    Derenzini, Massimo
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2006, 14 (03): : 314 - 323
  • [38] A prognostic index for operable, node-negative breast cancer
    M McCallum
    C Baker
    K Gillespie
    B Cohen
    H Stewart
    R Leonard
    D Cameron
    R Leake
    J Paxton
    A Robertson
    C Purdie
    A Gould
    M Steel
    British Journal of Cancer, 2004, 90 : 1933 - 1941
  • [39] Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells
    Vaidya, Kedar S.
    Sanchez, Jesus J.
    Kim, Eun Lim
    Welch, Danny R.
    CANCER LETTERS, 2009, 281 (01) : 100 - 107
  • [40] Hypoxia-inducible factor-1α correlates with MET and metastasis in node-negative breast cancer
    Helen H. W. Chen
    Wu-Chou Su
    Pin-Wen Lin
    How-Ran Guo
    Wen-Ying Lee
    Breast Cancer Research and Treatment, 2007, 103 : 167 - 175